Gilteritinib
About
Therapy type: Targeted therapy
Therapy strategy: FLT3 inhibition
Mappings
NCI Thesaurus: Gilteritinib (ncit:C116722)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | FLT3-ITD | Acute Lymphoid Leukemia | Gilteritinib | |
| FDA (1) | FLT3 p.D835Y | Acute Lymphoid Leukemia | Gilteritinib | |
| FDA (1) | FLT3 p.D835A | Acute Lymphoid Leukemia | Gilteritinib | |
| FDA (1) | FLT3 p.D835E | Acute Lymphoid Leukemia | Gilteritinib | |
| FDA (1) | FLT3 p.D835H | Acute Lymphoid Leukemia | Gilteritinib | |
| FDA (1) | FLT3 p.D835N | Acute Lymphoid Leukemia | Gilteritinib | |
| FDA (1) | FLT3 p.D835S | Acute Lymphoid Leukemia | Gilteritinib | |
| FDA (1) | FLT3 p.D835V | Acute Lymphoid Leukemia | Gilteritinib | |
| EMA (1) | FLT3-ITD | Acute Myeloid Leukemia | Gilteritinib | |
| EMA (1) | FLT3 p.D835Y | Acute Myeloid Leukemia | Gilteritinib |